These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20854386)

  • 1. Factors affecting improved glycaemic control in youth using insulin pumps.
    Wilkinson J; McFann K; Chase HP
    Diabet Med; 2010 Oct; 27(10):1174-7. PubMed ID: 20854386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.
    Hermanides J; Nørgaard K; Bruttomesso D; Mathieu C; Frid A; Dayan CM; Diem P; Fermon C; Wentholt IM; Hoekstra JB; DeVries JH
    Diabet Med; 2011 Oct; 28(10):1158-67. PubMed ID: 21294770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial.
    Battelino T; Conget I; Olsen B; Schütz-Fuhrmann I; Hommel E; Hoogma R; Schierloh U; Sulli N; Bolinder J;
    Diabetologia; 2012 Dec; 55(12):3155-62. PubMed ID: 22965294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of glycaemic control in patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
    Shalitin S; Gil M; Nimri R; de Vries L; Gavan MY; Phillip M
    Diabet Med; 2010 Mar; 27(3):339-47. PubMed ID: 20536498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability.
    Pickup JC; Kidd J; Burmiston S; Yemane N
    Diabetes Metab Res Rev; 2006; 22(3):232-7. PubMed ID: 16389648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial.
    O'Connell MA; Donath S; O'Neal DN; Colman PG; Ambler GR; Jones TW; Davis EA; Cameron FJ
    Diabetologia; 2009 Jul; 52(7):1250-7. PubMed ID: 19396424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes.
    Willi SM; Planton J; Egede L; Schwarz S
    J Pediatr; 2003 Dec; 143(6):796-801. PubMed ID: 14657831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countries.
    Danne T; Battelino T; Jarosz-Chobot P; Kordonouri O; Pánkowska E; Ludvigsson J; Schober E; Kaprio E; Saukkonen T; Nicolino M; Tubiana-Rufi N; Klinkert C; Haberland H; Vazeou A; Madacsy L; Zangen D; Cherubini V; Rabbone I; Toni S; de Beaufort C; Bakker-van Waarde W; van den Berg N; Volkov I; Barrio R; Hanas R; Zumsteg U; Kuhlmann B; Aebi C; Schumacher U; Gschwend S; Hindmarsh P; Torres M; Shehadeh N; Phillip M;
    Diabetologia; 2008 Sep; 51(9):1594-601. PubMed ID: 18592209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of blood glucose and HbA(1c) goals on glycaemic control in children and adolescents with Type 1 diabetes.
    Boot M; Volkening LK; Butler DA; Laffel LM
    Diabet Med; 2013 Mar; 30(3):333-7. PubMed ID: 23190135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data.
    Pickup JC; Freeman SC; Sutton AJ
    BMJ; 2011 Jul; 343():d3805. PubMed ID: 21737469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained benefit of continuous subcutaneous insulin infusion on glycaemic control and hypoglycaemia in adults with Type 1 diabetes.
    Beato-Víbora P; Yeoh E; Rogers H; Hopkins D; Amiel SA; Choudhary P
    Diabet Med; 2015 Nov; 32(11):1453-9. PubMed ID: 26213236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
    Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin.
    Blak BT; Smith HT; Hards M; Curtis BH; Ivanyi T
    Diabet Med; 2012 Jul; 29(7):e13-20. PubMed ID: 22268988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensification of diabetes medication and risk for 30-day readmission.
    Wei NJ; Wexler DJ; Nathan DM; Grant RW
    Diabet Med; 2013 Feb; 30(2):e56-62. PubMed ID: 23126686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia.
    Sulli N; Shashaj B
    J Pediatr Endocrinol Metab; 2003 Mar; 16(3):393-9. PubMed ID: 12705364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of injection-meal interval usage and its association with variables of metabolic control in patients with Type 1 and Type 2 diabetes.
    Müller N; Kloos C; Frank T; Ristow M; Wolf G; Müller UA
    Diabet Med; 2011 Feb; 28(2):223-6. PubMed ID: 21219434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of youths' glycemic control with insulin pump therapy.
    Nelson A; Genthe JA; Gall KM; Edwards E
    Pediatr Nurs; 2009; 35(4):234-9. PubMed ID: 19785303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
    Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.